Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders
Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
[引用][C] Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders
MF Tolba, HA Omar - Critical Reviews in Oncology/Hematology, 2018 - cir.nii.ac.jp
Immunotherapy, an evolving approach for the management of triple negative breast cancer:
Converting non-responders to responders | CiNii Research CiNii 国立情報学研究所 学術情報 …
Converting non-responders to responders | CiNii Research CiNii 国立情報学研究所 学術情報 …
Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders
MF Tolba, HA Omar - Critical reviews in oncology …, 2018 - pubmed.ncbi.nlm.nih.gov
Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
[PDF][PDF] Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders
MF Tolba, HA Omar - Critical Reviews in Oncology/Hematology, 2018 - bsu.edu.eg
Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders.
MF Tolba, HA Omar - Critical Reviews in Oncology/hematology, 2018 - europepmc.org
Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
[PDF][PDF] Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders
MF Tolba, HA Omar - Critical Reviews in Oncology/Hematology, 2018 - bsu.edu.eg
Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …